Effects of TRPV1 and TRPA1 activators on the cramp threshold frequency : a randomized, double-blind placebo-controlled trial

Gespeichert in:
Bibliographische Detailangaben
Deutscher übersetzter Titel:Auswirkungen von TRPV1- und TRPA1-Aktivatoren auf die Krampfschwellenfrequenz : eine randomisierte, doppelblinde, placebokontrollierte Studie
Autor:Behringer, Michael; Nowak, Stephanie; Leyendecker, Jannik; Mester, Joachim
Erschienen in:European journal of applied physiology
Veröffentlicht:117 (2017), 8, S. 1641–1647, Lit.
Format: Literatur (SPOLIT)
Publikationstyp: Zeitschriftenartikel
Medienart: Elektronische Ressource (online) Gedruckte Ressource
Sprache:Englisch
ISSN:1439-6319, 0301-5548
DOI:10.1007/s00421-017-3653-6
Schlagworte:
Online Zugang:
Erfassungsnummer:PU201807005034
Quelle:BISp

Abstract des Autors

Purpose: Previous data indicate that a strong sensory input from orally administered TRPV1 and TRPA1 activators alleviates muscle cramps in foot muscles by reducing the α-motor neuron hyperexcitability. We investigated if TRP activators increase the cramp threshold frequency of the medial gastrocnemius.
Methods: We randomly assigned 22 healthy male participants to an intervention (IG) and a control group (CG). While participants of the IG ingested a mixture of TRPV1 and TRPA1 activators, the CG received a placebo. We tested the cramp threshold frequency (CTF), the cramp intensity (EMG activity), and the perceived pain of electrically induced muscle cramps before (pre), and 15 min, 4, 8, and 24 h after either treatment. We further measured the maximal isometric force of knee extensors at pre, 4, and 24 h to assess potential side-effects on the force output.
Results: When we included all measurement time points, no group-by-time interaction was observed for the CTF. However, when only pre and 15 min values were incorporated, a significant interaction, with a slightly greater CTF increase in IG (3.1 +/- 1.5) compared to the CG (2.0 +/- 1.5), was observed. No significant group by time interaction was found for the cramp intensity, the perceived pain, and the maximal isometric force.
Conclusion: Our data indicate that orally administered TRPV1 and TRPA1 activators exert a small short-term effect on the CTF, but not on the other parameters tested. Future studies need to investigate whether such small CTF increments are sufficient to prevent exercise-associated muscle cramps.